Concert Pharma (CNCE) Misses Q4 EPS by 28c

Concert Pharma (NASDAQ: CNCE) reported Q4 EPS of ($1.01), $0.28 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $13 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• SanDisk upgraded at JPMorgan after investor day; shares climb